Switching from under-the-skin injections of Takhzyro (lanadelumab) to oral capsules of Orladeyo (berotralstat) was generally safe and kept the occurrence of swelling attacks at low rates over one year in people with hereditary angioedema (HAE), according to a new data analysis of the Phase 2/3 APeX-S trial.
Firazyr (icatibant injection) appears to be at least as safe and effective at controlling swelling attacks in hereditary angiodema (HAE) patients with normal C1 inhibitor (C1-INH) activity as among those with reduced or no C1-INH activity, according to real-world data from Brazilian patients. Most attacks were successfully treated with…
Regulatory health agencies in Canada and Switzerland have approved BioCryst Pharmaceuticals’ Orladeyo (berotralstat) as the first daily oral therapy to prevent hereditary angioedema (HAE) attacks. With these approvals, Orladeyo will be available in the two countries for the routine prevention of HAE attacks in patients ages 12 and…
A fully assembled, prefilled syringe form of Takeda’s Takhzyro (lanadelumab), approved to prevent swelling attacks in adults and children, ages 12 and older, with hereditary angioedema (HAE), is now available in the U.S. “HAE attacks are unpredictable, debilitating and in some cases life-threatening, adding uncertainty and complexity to the…
About one year of treatment with Takhzyro (lanadelumab) safely and effectively lowered the frequency of swelling attacks, while improving quality of life and treatment satisfaction in people with hereditary angioedema (HAE), according to interim data from the real-world EMPOWER study. In addition, nearly 1 in 5 patients was able to…
Long-term treatment with Orladeyo (berotralstat) at its approved 150 mg daily dose reduces the rate of swelling attacks significantly and improves quality of life for people with hereditary angioedema (HAE), according to nearly two years of data from the Phase 3 APeX-2 trial. These benefits were observed to…
The U.S. Food and Drug Administration (FDA) has approved the use of a prefilled syringe of Takeda’s Takhzyro (lanadelumab) to prevent swelling attacks in hereditary angioedema (HAE) patients, 12 and older. The prefilled syringe comes fully assembled and requires less preparation than the current vial-based injection of…
The richness and diversity of the gut’s microbial community, or microbiota, are significantly reduced in people with hereditary angioedema (HAE) who have had recent swelling attacks, when compared with that of healthy individuals, a single-center study in China shows. This difference was particularly pronounced among HAE patients with gastrointestinal…
Excess blood levels of uric acid — a normal body waste product — and Hashimoto’s disease, an autoimmune condition, may increase the risk of angioedema without hives for older adults, according to a study in Poland. Further studies are needed to confirm these findings and better understand the factors…
Ionis Pharmaceuticals has launched a registrational Phase 3 clinical trial to evaluate the safety and effectiveness of its investigational therapy donidalorsen, formerly known as IONIS-PKK-LRx, in people with hereditary angioedema (HAE) types 1 and 2. While the trial, called OASIS-HAE, may already be recruiting, information on recruitment status…
Get regular updates to your inbox.